Pharmacophore neuroleptic

Butaclamol s activity was ascribed to the presence of the neuroleptic pharmacophore within its extended phenethylamine moiety. Inspection of the structure of isobutaclamol reveals no such phenethylamine moiety, but instead, shows the presence of a phenyl propyl amine moiety. It thus appears that butaclamol and isobutaclamol are incapable of presenting the same pharmacophore to the DAR. We have therefore studied the molecular structures of butaclamol and isobutaclamol more closely with a view to resolving this apparent anomaly. 

A detailed study revealed that introduction of 1-alkyl-1, 3-dihydro-2H-benzimidazol-2-ones on known pharmacophores is compatible with neuroleptic (milenperone), antiemetic (domperidone, 7) and also with antihistaminic-antiallergic activity (oxatomide). 

---